Articles tagged "Liver transplantation"

2019 American Transplant Congress
Anti-Xa Level Monitoring for Treatment Dose Enoxaparin in Liver/Intestine Transplant Recipients
J. Sullivan, J. Jebrock, J. Revollo, M. Perez, J. Garcia, T. Beduschi
Jackson Memorial Hospital, Miami, FL
*Purpose: Evaluate the use of anti-Xa levels in therapeutic enoxaparin dosing in liver/intestine transplant recipients.*Methods: A single-center retrospective chart review was conducted on liver/intestine transplant…
2019 American Transplant Congress
Mismatched Antibody Epitopes and the Development of HLA-DQ De Novo DSA during Immunosuppression Withdrawal in Liver Transplant Recipients
V. Jucaud¹, A. Shaked², M. DesMarais³, P. Sayre⁴, S. Feng⁴, J. Levitsky⁵, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²University of Pennsylvania, Philadelphia, PA, ³Immune Tolerance Network, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Northern Western University, Chicago, IL
*Purpose: We recently described, in liver transplant (LT) recipients from the ITN030ST study, the development of de novo donor-specific HLA antibodies (dnDSA) and their impact…
2019 American Transplant Congress
Molecular Analysis of Rejection and Injury in Human Liver Transplant Biopsies: First Results of the INTERLIVER Study
P. F. Halloran and The INTERLIVER Study Group
University of Alberta, Edmonton AB, AB, Canada
*Purpose: The relationship of histologic liver transplant biopsy assessments to actual rejection and injury is unclear. Recent progress in molecular reclassification of kidney, heart, and…
2019 American Transplant Congress
Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation
N. Mehta¹, J. Guy², C. Frenette³, P. Tabrizian⁴, M. Hoteit⁵, R. Dhanasekaran⁶, J. Dodge¹, M. L. Holzner⁴, L. Frankul³, S. Florman⁴, N. Parikh⁷, F. Yao¹
¹UCSF, San Francisco, CA, ²CPMC, San Francisco, CA, ³Scripps Hospital, La Jolla, CA, ⁴Mt Sinai, New York, NY, ⁵U. Pennsylvania, Philadelphia, PA, ⁶Stanford, Palo Alto, CA, ⁷U. Michigan, Ann Arbor, MI
*Purpose: Recent studies from United Network of Organ Sharing (UNOS) Region 5 reported excellent outcomes after liver transplantation (LT) after successful down-staging in HCC patients…
2019 American Transplant Congress
Preemptive Therapy is Cost Effective When Compared to Prophylaxis in Cytomegalovirus Donor Positive – Recipient Negative Liver Transplant Recipients
M. M. Wagener¹, D. J. Winston², R. R. Razonable³, G. M. Lyon III⁴, F. P. Silveira⁵, A. P. Limaye⁶, N. Singh¹
¹ID, U Pittsburgh and VAPHS, Pittsburgh, PA, ²ID, UCLA, Los Angeles, CA, ³ID, Mayo Clinic, Rochester, MN, ⁴ID, Emory, Atlanta, GA, ⁵ID, U Pittsburgh, Pittsburgh, PA, ⁶ID, U Washington, Seattle, WA
*Purpose: To compare the cost effectiveness of preemptive therapy (PET) vs prophylaxis for the prevention of cytomegalovirus (CMV) in high-risk donor seropositive/recipient seronegative (D+R-) liver…
2019 American Transplant Congress
No Gains In Long-term Survival Of Pediatric Patients After Liver Transplantation – A Three Decade Analysis
S. Bakhtiyar, A. Rana, S. Ahmed, H. Naseem, M. Kueht, N. T. Galvan, R. T. Cotton, C. A. O'Mahony, J. A. Goss
Baylor College of Medicine, Houston, TX
*Purpose: The aim of this study was to assess improvements in long-term survival of pediatric patients after liver transplantation, by analyzing outcomes in transplant recipients…
2019 American Transplant Congress
Treatment Modality Affects Outcomes of Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A US Multicenter Analysis of 2786 Patients
P. Tabrizian¹, K. J. Halazun², M. L. Holzner¹, N. Mehta³, F. Y. Yao³, J. Roberts³, J. C. Emond⁴, B. Samstein², R. S. Brown⁴, S. Florman¹, M. E. Schwartz¹, M. M. Doyle⁵, W. C. Chapman⁵, M. Najjar⁴, R. W. Busuttil⁶, V. G. Agopian⁶
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Transplant, Weill Cornell Medicine, New York, NY, ³Transplant, University of California San Francisco, San Francisco, CA, ⁴Transplant, Columbia University Medical Center, New York, NY, ⁵Transplant, Washington University School of Medicine, St Louis, MO, ⁶Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) has a poor prognosis. We evaluated the impact of treatment modalities on post-recurrence survival.*Methods: Adult patients…
2019 American Transplant Congress
Renal Safety Of Entecavir And Tenofovir With Hepatitis B Immunoglobulin In Liver Transplant Patients
D. Kim¹, J. Lee¹, E. Kim¹, S. Kim¹, K. Ihn¹, D. Joo¹, K. Huh¹, B. Kim², M. Kim¹, S. Kim¹, Y. Kim¹, J. Lee¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…
2019 American Transplant Congress
Liver Transplantation for Acute Liver Failure: A 16 Year Experience with 214 Patients in the Post-MELD Era
R. McMillan, T. Ito, A. Aziz, A. Amin, A. Murray, J. DiNorcia III, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas
Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA
*Purpose: Liver transplantation (LT) remains the gold standard treatment for acute liver failure (ALF). Our center has previously reported outcomes in the pre-Model for End…
2019 American Transplant Congress
CD47 Blockade Promotes Hepatic Macrophage Polarization toward M1 during Normothermic Machine Perfusion of Discarded Human Livers
M. Xu¹, F. Zhou¹, S. Garcia-Aroz¹, B. Banan¹, W. Yang², G. Upadhya¹, K. Byrnes³, B. Wong¹, P. Manning⁴, Y. Lin¹, W. Chapman¹
¹Department of Surgery, Washington University School of Medicine, St. Louis, MO, ²Department of Genetics, Washington University School of Medicine, St. Louis, MO, ³Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ⁴Arch Oncology, St. Louis, MO, USA, St. Louis, MO
*Purpose: M1 macrophages have been shown to be able to phagocytize dead cells after ischemia-reperfusion injury (IRI). This study investigated the therapeutic effect of CD47…